Establishing Suspension Cell Cultures for Improved Manufacturing of Oncolytic Adenovirus

Ana Sofia Moreira, Ana Carina Silva, Marcos F.Q. Sousa, Åsa Hagner-McWhirterc, Gustaf Ahlénc, Mats Lundgren, Ana S. Coroadinha, Paula M. Alves, Cristina Peixoto, Manuel J.T. Carrondo

Research output: Contribution to journalArticlepeer-review

Abstract

Recent clinical trials have shown the potential of oncolytic adenoviruses as a cancer immunotherapy. A successful transition of oncolytic adenovirus to clinical applications requires efficient and good manufacturing practice compatible production and purification bioprocesses. Suspension cultures are preferable for virus production as they can reduce process costs and increase product quality and consistency. This work describes the adaptation of the A549 cell line to suspension culture in serum-reduced medium validated by oncolytic adenovirus production in stirred tank bioreactor. Cell concentrations up to 3 × 106 cells mL−1 are obtained during the production process. At harvest 1.4 × 1010 infectious particles mL−1 and 6.9 ± 1.1 × 1010 viral genome mL−1 are obtained corresponding to a viral genome: infectious particles ratio of 5.2 (± 1.9): 1 confirming the virus quality. Overall, the suspension characteristics of these A549 cells support an easily scalable, less time-consuming, and more cost-effective process for expanded success in the use of oncolytic viruses for cancer therapy.

Original languageEnglish
Article number1900411
JournalBiotechnology Journal
Volume15
Issue number4
DOIs
Publication statusPublished - 1 Apr 2020

Keywords

  • A549 cell line
  • gene therapy
  • oncolytic adenovirus
  • scalable
  • suspension

Fingerprint Dive into the research topics of 'Establishing Suspension Cell Cultures for Improved Manufacturing of Oncolytic Adenovirus'. Together they form a unique fingerprint.

Cite this